Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-B7-H4/anti-CD3 bispecific antibody GEN1047

A bispecific monoclonal antibody against both B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H4/anti-CD3 bispecific antibody GEN1047 targets and binds to both B7-H4 on the surface of tumor cells and CD3 on T cells. This results in the cross-linking of tumor cells and T cells, and induces a cytotoxic T-lymphocyte (CTL) response against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:DuoBody-CD3xB7H4 GEN1047
Code name:GEN 1047
GEN-1047
GEN1047
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search